Sign Out
Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion, with the effect of increasing the elimination half-life and plasma concentration of meropenem. As the potency and duration of action of meropenem dosed without probenecid are adequate, the co-administration of probenecid with meropenem is not recommended.
The potential effect of meropenem on the protein binding of other drugs or metabolism has not been studied. The protein binding of meropenem is low (approximately 2%) and therefore no interactions with other compounds based on displacement from plasma proteins would be expected.
Meropenem may reduce serum valproic acid levels and anticonvulsant effect. Subtherapeutic levels may be reached in some patients.
Concurrent use of live typhoid vaccine and antibiotics may result in a decreased immunological response to the typhoid vaccine.
